A first-in-human, partially randomized and placebo-controlled phase I trial examined the safety, tolerability, pharmacokinetics and antiviral activity of the bispecific 10E8.4/iMab broadly neutralizing monoclonal antibody in people living with or without HIV, and found it was safe and well tolerated at different dose levels and routes of administration.